Benralizumab is an anti-eosinophilic, anti-interleukin-5 receptor α monoclonal antibody that has been shown to significantly reduce asthma exacerbations and improve lung function for patients with severe, uncontrolled asthma. We further explored the efficacy of benralizumab for patients with different baseline blood eosinophil thresholds and exacerbation histories.

中文翻译：

---

贝拉珠单抗对重度哮喘患者反应增强的预测指标：SIROCCO和CALIMA研究的合并分析。

Benralizumab是一种抗嗜酸性粒细胞的抗白细胞介素5受体α单克隆抗体，对于患有严重，无法控制的哮喘的患者，已证明可显着减少哮喘的发作并改善其肺功能。我们进一步探讨了贝那利珠单抗对具有不同基线血液嗜酸性粒细胞阈值和病情加重史的患者的疗效。